| Literature DB >> 33267877 |
Lingyu Xu1,2, Joseph J Pagano1, Mark J Haykowksy3, Justin A Ezekowitz2,4, Gavin Y Oudit2, Yoko Mikami5,6, Andrew Howarth5,6, James A White5,6, Jason R B Dyck7, Todd Anderson8, D Ian Paterson2, Richard B Thompson9.
Abstract
BACKGROUND: Global longitudinal strain (GLS), most commonly measured at the endocardium, has been shown to be superior to left ventricular (LV) ejection fraction (LVEF) for the identification of systolic dysfunction and prediction of outcomes in heart failure (HF). We hypothesized that strains measured at different myocardial layers (endocardium = ENDO, epicardium = EPI, average = AVE) will have distinct diagnostic and predictive performance for patients with HF.Entities:
Keywords: Cardiovascular magnetic resonance imaging; Feature tracking; Heart failure; Layer-specific global longitudinal strain; Prognosis
Year: 2020 PMID: 33267877 PMCID: PMC7713324 DOI: 10.1186/s12968-020-00680-6
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Strain Method. a Registration of cine images is used to calculate pixel-wise displacement fields between each image frame and the reference frames. b The process of registration yields displacement images (∆x, ∆y) that contain the translation of each pixel from the reference frame to the target ith image frame. c The user specifies endocardial (red) and epicardial (green) points on the end-diastolic frame. A uniform grid of points is generated at end-diastole consisting of 20 equally spaced contours between the user-specified endocardial and epicardial tracings from, with 100 equally spaced points along each contour. d Each point, or equivalently, each series of points in a contour, is propagated to all other cardiac phases using the previously calculated displacement fields. Four sample contours are shown. Strain for each contour is calculated as the fraction change in the contour length to end-systole. For regions that contain multiple contours, as shown here for GLS_AVE and GRS, average strains are calculated as the average of the strains from the individual contours. GLS_AVE, average global longitudinal strain; GRS, global radial strain
Fig. 2Layer-specific contours in long axis cine images, at endocardial (red), epicardial (green) and equally spaced intramyocardial contours (blue) at end-diastole and end-systole used for the calculation of layer-specific strain. A subset of the 20 total intramyocardial contours used for calculation of average strain are shown. Sample tracings for a four-chamber view are shown for a health control (top) and a patient with heart failure (HF) with preserved ejection fraction (HFpEF) (bottom). Strain values at each layer over the full cardiac cycle are shown on the right
Fig. 3Layer-specific contours in short axis cine images, at endocardial (red), epicardial (green) and equally spaced intramyocardial contours (blue) at end-diastole and end-systole used for the calculation of layer-specific strain. A subset of the 20 total intramyocardial contours used for calculation of average strain are shown. Sample tracings for a mid-ventricular short-axis view are shown for a health control (top) and a patient with HFpEF (bottom). Strain values at each layer over the full cardiac cycle are shown on the right
Baseline Characteristics in the 5 Subgroups of Subjects
| Healthy controls (n = 70) | At risk for heart failure (n = 126) | HFpEF | p-value 1 | HFmrEF | HFrEF | p-value 2 | |
|---|---|---|---|---|---|---|---|
| Preserved ejection fraction | |||||||
| Age, year | 59 (52,69)*† | 65 (60,72)* | 73 (64,81) | < 0.001 | 70 (60,75)¶ | 66 (59,77)¶ | 0.005 |
| Male | 29 (37.1%) | 53 (42.1%) | 34 (39.1%) | 0.78 | 61 (69.3%) | 40 (69.0%) | < 0.001 |
| BMI, (kg/m2) | 28 (24,30)*† | 29 (25,34)* | 30 (28,35) | < 0.001 | 29 (26,33)¶ | 29 (26,32)¶ | 0.013 |
| Systolic blood pressure, (mmHg) | 128 (116,140)† | 137 (123,151) | 130 (121,146) | 0.070 | 125 (115,136)¶ | 124 (111,133)¶ | 0.006 |
| Heart rate, bpm | 67 (60,76) | 68 (61,76) | 64 (60,76) | 0.16 | 64 (60,75) | 68 (60,76) | 0.30 |
| NYHA Class | 2.1 ± 0.7 | N/A | 1.9 ± 0.7 | 2.0 ± 0.7 | 0.30 | ||
| Coronary artery disease | 0 | 22 (17.5%) | 37 (42.5%) | < 0.001 | 40 (45.5%) | 29 (50%) | 0.68 |
| Hypertension | 0 | 100 (79.4%) | 75 (86.2%) | < 0.001 | 56 (63.6%) | 37 (63.8%) | 0.001 |
| Atrial fibrillation/flutter | 0 | 19 (15.1%) | 34 (39.1%) | < 0.001 | 36 (40.9%) | 23 (39.7%) | 0.98 |
| Chronic obstructive pulmonary disease | 0 | 8 (6.4%) | 18 (20.1%) | < 0.001 | 15 (17.1%) | 12 (20.7%) | 0.79 |
| Chronic kidney disease | 0 | 9 (7.1%) | 22 (25.3%) | < 0.001 | 17 (19.3%) | 11 (19.0%) | 0.55 |
| Beta blocker | 0 | 34 (27.0%) | 64 (73.6%) | < 0.001 | 79 (89.8%)¶ | 54 (93.1%)¶ | 0.001 |
| ACEi or ARB | 0 | 86 (68.3%) | 73 (83.9%) | < 0.001 | 76 (83.6%) | 50 (86.2%) | 0.88 |
| NT-proBNP (pmol/l) | 5 (3,10)*† | 7 (4,16)* | 66 (19,132) | < 0.001 | 57 (24,147) | 104 (52,253)¶§ | 0.003 |
| Creatinine (mol/l) | 78 (67,86)* | 77 (67,89)* | 96 (76,123) | < 0.001 | 97 (80,122) | 93 (77,110) | 0.49 |
HFpEF heart failure with preserved ejection fraction, HFmrEF heart failure with midrange ejection fraction, HFrEF heart failure with reduced ejection fraction, BMI body mass index, NYHA New York Heart Association Classification, COPD chronic obstructive pulmonary disease, ACEI Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, NT-proBNP N-terminal pro b-type natriuretic peptide
p-values 1 were derived from comparison among the three subgroups with preserved ejection fraction and p-values 2 for the three subgroups of patients with heart failure
*Significantly different from HFpEF in comparison among 3 subgroups with preserved LVEF
†Significantly different from patients at risk for heart failure in comparison among three subgroups with preserved LVEF
¶Significantly different from HFpEF in comparison among three subgroups with heart failure
§Significantly different from HFmrEF in comparison among three subgroups with heart failure
Continuous variables were expressed as mean ± standard deviation or median (25th, 75th percentile), as appropriate
Cardiac structure and functions in the 5 subgroups of subjects
| Healthy controls (n = 70) | At risk for heart failure (n = 126) | HFpEF (n = 87) | p-value 1 | HFmrEF (n = 88) | HFrEF (n = 58) | p-value 2 | |
|---|---|---|---|---|---|---|---|
| Preserved ejection fraction | |||||||
| LVEF (%) | 63 (61,67)† | 66 (62,70)* | 63 (59,68) | 0.008 | 48 (44,52) ¶ | 32 (25,38)¶§ | < 0.001 |
| LVEDVI (ml/m2) | 74 (68,83) | 75 (65,87) | 76 (68,86) | 0.73 | 100 (81,114)¶ | 134 (100,165)¶§ | < 0.001 |
| LVESVI (ml/m2) | 27 (23,31) | 25 (21,31) | 28 (22,33) | 0.16 | 51 (40,62)¶ | 90 (64,121)¶§ | < 0.001 |
| LVM index, (g/m2) | 55 (49,61)*† | 61 (51,71)* | 66 (56,79) | < 0.001 | 76 (63,88)¶ | 91 (74,110)¶§ | < 0.001 |
| LVM/LVEDV | 0.72 (0.66,0.79)*† | 0.80 (0.70,0.91)* | 0.85 (0.73,0.98) | < 0.001 | 0.79 (0.66,0.88)¶ | 0.67 (0.60,0.76)¶§ | < 0.001 |
| RWT | 0.31 (0.27,0.34) * | 0.32 (0.28,0.37)* | 0.34 (0.29,0.40) | 0.019 | 0.32 (0.27,0.37)¶ | 0.28 (0.24,0.32)¶§ | < 0.001 |
| RVEF | 58 (55,64)† | 62 (57,67) * | 60 (52,64) | 0.021 | 52 (46,58)¶ | 49 (41,56)¶§ | < 0.001 |
| RVEDVI, (ml/m2) | 74 (63,83) | 75 (61,88) | 71 (63,91) | 0.74 | 81 (67,97)¶ | 79 (68,108)¶ | 0.070 |
| RVESVI, (ml/m2) | 30 (23,35) | 28 (22,35) | 31 (24,39) | 0.27 | 38 (28,48)¶ | 39 (31,57)¶ | < 0.001 |
| GLS_EPI (%) | − 16.5 ± 2.4*† | − 15.5 ± 2.7* | − 14.1 ± 3.0 | < 0.001 | − 11.6 ± 2.1¶ | − 8.2 ± 2.2¶§ | < 0.001 |
| GLS_AVE (% | − 19.6 ± 2.5* | − 19.2 ± 3.1* | − 17.9 ± 3.3 | < 0.001 | − 14.0 ± 2.3¶ | − 9.4 ± 2.7¶§ | < 0.001 |
| GLS_ENDO (%) | − 21.1 ± 2.6 | − 21.2 ± 3.4 | − 20.1 ± 3.7 | 0.050 | − 15.3 ± 2.9¶ | − 10.0 ± 3.2¶§ | < 0.001 |
| GLS_ENDO/GLS_EPI | 1.3 (1.2,1.4)*† | 1.4 (1.3,1.5)* | 1.4 (1.3,1.5) | < 0.001 | 1.3 (1.2,1.4)¶ | 1.2 (1.2,1.3)¶§ | < 0.001 |
| Absolute GLS layer difference, (%) | − 4.7 (− 5.8, − 3.3)*† | − 5.7 (− 7.4, − 4.1) | − 5.6 (− 7.5, − 4.3) | < 0.001 | − 3.5 (− 5.1, − 2.3)¶§ | − 2.1 (− 2.7, − 1.0)¶§ | < 0.001 |
| Relative GLS layer difference (%) | 21.9 (16.5,27.0)*† | 27.3 (20.4,32.5)* | 28.9 (23.4,34.4) | < 0.001 | 25.4 (16.1,29.9)¶§ | 17.9 (13.4,25.8)¶§ | < 0.001 |
| GCS_EPI (%) | − 11.1 ± 2.8 | − 10.2 ± 2.5 | − 10.2 ± 3.4 | 0.072 | − 7.8 ± 2.4¶ | − 5.7 ± 2.2¶§ | < 0.001 |
| GCS_AVE (%) | − 19.9 ± 3.4 | − 19.9 ± 3.3 | − 19.3 ± 4.0 | 0.40 | − 13.9 ± 3.1¶ | − 9.3 ± 3.1¶§ | < 0.001 |
| GCS_ENDO (%) | − 29.9 ± 4.7 | − 31.1 ± 5.3 | − 29.9 ± 6.1 | 0.17 | − 21.1 ± 4.9¶ | − 13.1 ± 4.6¶§ | < 0.001 |
| GCS_ENDO/GCS_EPI | 2.6 (2.4,3.1)*† | 3.0 (2.6,3.6) | 2.9 (2.4,4.0) | 0.004 | 2.6 (2.3,3.3)¶ | 2.3 (1.9,2.9)¶§ | < 0.001 |
| Absolute GCS layer difference (%) | − 18.8 (− 21.1, − 16.3)† | − 20.8 (− 24.3, − 17.8)* | − 19.0 (− 23.1, − 16.1) | 0.002 | − 13.0 (− 16.2, − 9.8)¶ | − 7.5 (− 8.7, − 5.1)¶§ | < 0.001 |
| Relative GCS layer difference (%) | 61.8 (58.4,67.5) *† | 67.0 (62.1,72.1) | 65.4 (57.8,74.8) | 0.004 | 62.0 (57.1,69.2)¶ | 56.8 (47.4,64.9)¶§ | < 0.001 |
| GRS_LAx (%) | 48.9 ± 10.7* | 47.5 ± 12.8* | 41.1 ± 13.8 | < 0.001 | 28.5 ± 9.4¶ | 18.7 ± 7.7¶§ | < 0.001 |
| GRS_SAx (%) | 46.7 ± 12.4* | 46.3 ± 15.1* | 38.6 ± 16.7 | < 0.001 | 27.0 ± 9.0¶ | 17.7 ± 8.1¶§ | < 0.001 |
HFpEF heart failure with preserved ejection fraction; HFmrEF heart failure with midrange ejection fraction; HFrEF heart failure with reduced ejection fraction; LVEF left ventricular ejection fraction; LVEDVI left (right) ventricular end-diastolic volume indexed to ideal body surface area; LVESVI left (right) ventricular end-systolic volume indexed to ideal body surface area; LVM left ventricular mass; RVEF right ventricular ejection fraction, RVEDVI right ventricular end-diastolic volume index; RVESVI right ventricular end-systolic volume index, RWT relative wall thickness; GLS_EPI epicardial global longitudinal strain; GLS_AVE average global longitudinal strain; GLS_ENDO endocardial global longitudinal strain; GCS_EPI picardial global circumferential strain; GCS_AVE average global circumferential strain; GCS_ENDO endocardial global circumferential strain; GRS global radial strain; LAx long axis; SAx short axis
Absolute strain layer difference = endocardial strain—epicardial strain; relative strain layer difference = (endocardial strain—epicardial strain)/endocardial strain
p-values 1 were derived from comparison among the three subgroups with preserved ejection fraction and p-value 2 for the three subgroups of patients with heart failure
*Significantly different from HFpEF in comparison among three subgroups with preserved LVEF
†Significantly different from patients at risk for heart failure in comparison among three subgroups with preserved LVEF
¶Significantly different from HFpEF in comparison among three subgroups with heart failure
§Significantly different from HFmrEF in comparison among three subgroups with heart failure
Continuous variables were expressed as mean ± standard deviation or median (25th, 75th percentile), as appropriate
Fig. 4Scatter and box plots of LV ejection fraction (LVEF) (a) and epicardial global longitudinal strain (GLS_EPI) (b) in all five groups. For each group, box plots show the median value, 25th and 75th percentiles and the full extent of the data. Outliers are identified as unfilled circles in the box plot. Scatter and box plots for LVEF (c and e) and GLS_EPI (d and f) in the preserved LVEF groups are shown with grouping by sex. Individuals with reduced GLS_EPI values are contained within the dashed boxes in d (men: 11% of controls, 17% of the at risk group and 32% of HFpEF are within the box) and f (women: 9% of healthy controls, 14% of the at risk group and 45% of HFpEF are within the box). All subjects in the preserved LVEF groups have normal LVEF by definition
Fig. 5Scatter and box plots for LVEF and all strain components for all five groups. Box plots show the median value, 25th and 75th percentiles and the full extent of the data. Outliers are identified as unfilled circles in the box plot
Fig. 6Relationship between GRS and LV Mass / LVEDV (concentricity) in HFpEF patients (a and b) and in all subjects with preserved LVEF (c and d). See Table 2 for abbreviations
Comparison of layer-specific strain, LV mass and relative wall thickness between two sexes in healthy controls
| Male (n = 29) | Female (n = 48) | p-value | |
|---|---|---|---|
| LVEF (%) | 62 (59,65) | 63 (60,67) | 0.50 |
| GLS_EPI (%) | − 15.0 ± 2.4 | − 17.1 ± 2.3 | < 0.001 |
| GLS_AVE (%) | − 18.7 ± 2.6 | − 20.5 ± 2.5 | 0.006 |
| GLS_ENDO (%) | − 19.6 ± 2.6 | − 21.4 ± 2.7 | 0.005 |
| GLS_ENDO/GLS_EPI | 1.32 ± 0.12 | 1.26 ± 0.11 | 0.035 |
| Absolute GLS layer difference, % | − 5.0 (− 5.6, − 3.8) | − 4.2 (− 5.6, − 3.2) | 0.33 |
| Relative GLS layer difference, % | 24.2 (20.1,28.0) | 19.7 (15.6,25.7) | 0.030 |
| GCS_EPI (%) | − 9.6 ± 2.6 | − 11.6 ± 2.7 | 0.002 |
| GCS_AVE (%) | − 18.5 ± 3.3 | − 20.1 ± 3.4 | 0.051 |
| GCS_ENDO (%) | − 28.9 ± 4.7 | − 29.7 ± 4.9 | 0.50 |
| GCS_ENDO/GCS_EPI | 2.97 (2.61,3.47) | 2.56 (2.32,2.86) | 0.001 |
| Absolute GCS layer difference (%) | − 18.7 (− 21.7, − 16.6) | − 18.3 (− 20.4, − 15.8) | 0.29 |
| Relative GCS layer difference (%) | 66.3 (61.6,71.2) | 61.0 (56.9,65.1) | 0.001 |
| GRS_LAx (%) | 43.6 ± 10.6 | 50.6 ± 10.3 | 0.006 |
| GRS_SAx (%) | 41.7 ± 11.7 | 49.1 ± 12.2 | 0.011 |
| LVM index,g/m2 | 60 (57,71) | 52 (47,57) | 0.005 |
| LVM/LVEDV | 0.81 (0.70,0.93) | 0.74 (0.64,0.83) | < 0.001 |
| RWT | 0.34 (0.30,0.37) | 0.30 (0.26,0.32) | < 0.001 |
Continuous variables were expressed as mean ± standard deviation or median (25th, 75th percentile), as appropriate
p-values were derived from comparison between two sexes
Cox proportional hazard regression analysis for the outcome of 5-year all-cause mortality
| Patients with HF or at risk for HF- 376 subjects (33 events) | |||||
|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | ||||
| HR (95% CI) | p-value | Model χ2 | HR (95% CI) | p-value | |
| Age at CMR, per 10 year increase | 2.37 (1.58,3.56) | < 0.001 | 21.5 | ||
| Male gender | 0.66 (0.32,1.34) | 0.25 | 1.4 | ||
| BMI, per 1 kg/m2 increase | 1.00 (0.94,1.06) | 0.99 | 0.1 | ||
| Systolic blood pressure, per 10 mmHg increase | 0.80 (0.66,0.98) | 0.031 | 0.2 | ||
| Current smoker | 1.34 (0.93,1.91) | 0.12 | 2.6 | ||
| History of heart failure | 6.43 (1.96,21.08) | 0.002 | 15.3 | ||
| Hypertension | 1.07 (0.48,2.38) | 0.86 | 0.1 | ||
| Coronary artery disease | 2.15 (1.11,4.17) | 0.023 | 5.1 | ||
| Atrial fibrillation/flutter | 2.81 (1.42,5.58) | 0.003 | 8.6 | ||
| Diabetes | 0.81 (0.39,1.70) | 0.58 | 0.3 | ||
| COPD | 1.92 (0.87,4.26) | 0.11 | 2.3 | ||
| Chronic kidney disease | 1.20 (0.50,2.91) | 0.69 | 0.2 | ||
| Log (NT-proBNP), per 1 unit increase | 1.84 (1.44,2.36) | < 0.001 | 27.5 | ||
| Log (Creatinine), per 1 unit increase | 3.20 (1.37,7.49) | 0.007 | 6.2 | ||
| LVEF, per 10% decrease | 1.37 (1.10,1.71) | 0.004 | 7.6 | 1.22 (0.95,1.58) | 0.12 |
| LVEDVI, per 10 ml/m2 increase | 1.09 (1.00,1.18) | 0.043 | 3.5 | 1.06 (0.97,1.15) | 0.19 |
| LVESVI, per 10 ml/m2 increase | 1.11 (1.02,1.20) | 0.013 | 5.0 | 1.07 (0.97,1.17) | 0.16 |
| LVM index, per 10 g/m2 increase | 1.14 (1.00,1.29) | 0.051 | 3.3 | 1.09 (0.95,1.25) | 0.25 |
| LVM/LVEDV, per 0.1 increase | 0.98 (0.82,1.17) | 0.82 | 0.1 | 0.92 (0.81,1.03) | 0.14 |
| GLS_EPI, per 1% absolute decrease | 1.11 (1.04,1.18) | 0.002 | 9.4 | 1.09 (0.98,1.22) | 0.11 |
| GLS_AVE, per 1% absolute decrease | 1.14 (1.06,1.23) | < 0.001 | 12.5 | 1.10 (1.01,1.20) | 0.023 |
| GLS_ENDO, per 1% absolute decrease | 1.10 (1.04, 1.18) | 0.002 | 9.2 LR chi2 (2) = 1 LR chi2 (2) = 1 | 1.06 (0.98, 1.15) | 0.15 |
| GCS_EPI, per 1% absolute decrease | 1.01 (0.91,1.13) | 0.83 | 0.1 | 0.99 (0.90,1.10) | 0.87 |
| GCS_AVE, per 1% absolute decrease | 1.05 (0.99, 1.12) | 0.10 | 2.6 | 1.02 (0.95,1.09) | 0.57 |
| GCS_ENDO, per 1% absolute decrease | 1.04 (1.00,1.08) | 0.044 | 4.0 | 1.02 (0.98,1.06) | 0.41 |
| GRS_LAx, per 1% decrease | 1.03 (1.01,1.05) | 0.001 | 12.2 | 1.03 (1.00,1.05) | 0.024 |
| GRS_SAx, per 1% decrease | 1.03 (1.01,1.05) | 0.002 | 11.9 | 1.03 (1.00,1.05) | 0.019 |
Base model: age + log (NT-proBNP)
See Tables 1, 2 for abbreviations
Discrimination performance of layer-specific Strains by Akaike information Criterion (AIC) for death at 5 years
| AIC | ΔAIC | |
|---|---|---|
| BM + LVEF | 355.7 | 3.7 |
| BM + LVEDVI | 356.5 | 4.5 |
| BM + LVESVI | 356.4 | 4.4 |
| BM + LVM indexi | 356.9 | 4.9 |
| BM + GLS_EPI | 355.5 | 3.5 |
| BM + GLS_AVE | 352.8 | 0.8 |
| BM + GLS_ENDO | 355.7 | 3.7 |
| BM + GCS_EPI | 358.1 | 6.1 |
| BM + GCS_AVE | 357.5 | 5.5 |
| BM + GCS_ENDO | 357.4 | 5.4 |
| BM + GRS_LAx | 352.3 | 0.3 |
| BM + GRS_SAx | 352.0 | 0 |
BM base model, including age and log (NT-proBNP).
ΔAIC = AIC—AIC (AIC = AICGRS_SAX). The model with lowest AIC score (AICminimum) indicates the best model. See Table 2 for abbreviations.